In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Rezolute, with a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison has given his Buy rating due to a combination of factors that highlight the potential of Rezolute’s drug, ersodetug, in treating congenital hyperinsulinism (cHI). The Phase 3 sunRIZE trial data, which align with the previous Phase 2b RIZE trial, suggest a promising outcome for the topline results expected in December 2025. The trial’s baseline characteristics indicate that many patients were inadequately controlled on the current standard of care, diazoxide, which supports the need for a more effective treatment option.
Harrison anticipates that ersodetug will become the preferred treatment for patients who are refractory or intolerant to the current standard of care and may eventually be used as a first-line treatment. The drug’s potential safety and efficacy advantages could address the significant unmet need in the cHI patient population, which numbers over 3,500 in the US alone. With a substantial initial target market of diazoxide-unresponsive patients, the financial prospects for Rezolute are promising, further justifying the Buy rating.
In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $12.00 price target.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RZLT in relation to earlier this year.